Mitsubishi Tanabe to market Sun Pharma's newly-acquired drugs in Japan

6 September 2016

Japanese drugmaker Mitsubishi Tanabe Pharma (TYO: 4508) will market and distribute 14 long-listed branded drugs in Japan which were acquired earlier this year by India’s Sun Pharmaceutical Industries (BSE: 524715) from Swiss pharma giant Novartis (NOVN: VX).

These 14 brands – for indications ranging from epilepsy and depression to skin conditions – will be transferred from Novartis to Sun Pharma’s subsidiary in Japan, beginning in October this year.

Following the transfer of the manufacturing and marketing rights to Sun Pharma’s subsidiary in Japan, Mitsubishi Tanabe will market and distribute the drugs as well as provide information on their proper use to healthcare professionals.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK